World

No. 2 House Republican Steve Scalise diagnosed with blood cancer, undergoing treatment

Associated Press
By Associated Press
2 Min Read Aug. 29, 2023 | 2 years Ago
Go Ad-Free today

WASHINGTON — Rep. Steve Scalise, the No. 2-ranking House Republican, said Tuesday he has been diagnosed with a form of blood cancer known as multiple myeloma and is undergoing treatment.

Scalise, 57, said he will continue to serve in the House. He described the cancer as “very treatable” and said it was detected early.

The Louisiana Republican was among several people wounded in 2017 when a rifle-wielding attacker fired on lawmakers on a baseball field in Alexandria, Virginia, outside Washington. Scalise was shot in the hip and endured lengthy hospitalizations, multiple surgeries and painful rehabilitation.

The cancer diagnosis came, Scalise said, after he had not been feeling like himself in the past week. Blood tests showed some irregularities and after additional screening, he said he was diagnosed with multiple myeloma.

“I have now begun treatment, which will continue for the next several months,” Scalise said in a statement. “I expect to work through this period and intend to return to Washington, continuing my work as Majority Leader and serving the people of Louisiana’s First Congressional District.”

Scalise also thanked his medical team and said he was “incredibly grateful we were able to detect this early and that this cancer is treatable.”

“I will tackle this with the same strength and energy as I have tackled past challenges,” Scalise said.

Share

Categories:

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options